Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
| Autor: | Eva Havrdova, Dana Horakova, Pierre Grammond, Roberto Bergamaschi, Murat Terzi, Jeanette Lechner-Scott, Eugenio Pucci, Pierre Duquette, C. Ramo-Tello, Cavit Boz, Tim Spelman, Diana Ferraro, Guillermo Izquierdo, Patrizia Sola, Tomas Kalincik, Daniele Spitaleri, Marc Girard, Francois Grand'Maison, Vilija Jokubaitis, Vincent Van Pesch, Maria Trojano, Franco Granella, Alexandre Prat, Helmut Butzkueven, Alessandra Lugaresi, Celia Oreja-Guevara, G. Iuliano, Johannes Lorscheider |
|---|---|
| Přispěvatelé: | DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE, OMÜ, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Neurologie (9), Klinische Neurowetenschappen |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male MULTICENTER Anti-Inflammatory Agents TREATMENT TRIALS multiple sclerosis Anti-Inflammatory Agents/therapeutic use DOUBLE-BLIND Disability Evaluation 0302 clinical medicine Recurrence Longitudinal Studies GLATIRAMER ACETATE treatment Multiple Sclerosis Chronic Progressive/diagnostic imaging Hazard ratio Middle Aged Multiple Sclerosis Chronic Progressive Magnetic Resonance Imaging multiple sclerosis treatment progression Treatment Outcome Area Under Curve Disease Progression Female medicine.drug Cohort study Adult medicine.medical_specialty Article 03 medical and health sciences Internal medicine medicine SWITCH Humans Glatiramer acetate Propensity Score Proportional Hazards Models Expanded Disability Status Scale business.industry Proportional hazards model Interferon beta-1a MS Confidence interval FINGOLIMOD 030104 developmental biology REMITTING MULTIPLE-SCLEROSIS Propensity score matching INTERFERON-BETA-1A Neurology (clinical) progression business 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Petersen, T & MSBase Study Group 2017, ' Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS ', Neurology, vol. 89, no. 10, pp. 1050-1059 . https://doi.org/10.1212/WNL.0000000000004330 Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Neurology, 89(10), 1050-1059. LIPPINCOTT WILLIAMS & WILKINS Neurology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 0028-3878 |
| Popis: | Kermode, Allan/0000-0002-4476-4016; Ferraro, Diana/0000-0003-4818-3806; Lugaresi, Alessandra/0000-0003-2902-5589; Jokubaitis, Vilija G./0000-0002-3942-4340; McCombe, Pamela/0000-0003-2704-8517; Ramo-Tello, Cristina M/0000-0001-8643-5053; Oreja-Guevara, Celia/0000-0002-9221-5716; Havrdova, Eva Kubala/0000-0002-9543-4359; Vucic, Steve/0000-0002-8323-873X; Kalincik, Tomas/0000-0003-3778-1376; Slee, Mark/0000-0003-4323-2453; Prat, Alexandre/0000-0001-6188-0580; Sanchez Menoyo, Jose Luis/0000-0003-2634-8294; van Pesch, Vincent/0000-0003-2885-9004; Trojano, Maria/0000-0002-6329-8946; Butzkueven, Helmut/0000-0003-3940-8727; Lorscheider, Johannes/0000-0003-1100-2506; pucci, eugenio/0000-0001-7606-7330; Petersen, Thor/0000-0001-5633-2600 WOS: 000409172500017 PubMed: 28794248 Objective: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously validated a highly accurate definition of SPMS. Here, we identified patients in MSBase who were either untreated or treated with a disease-modifying drug when meeting this definition. Propensity score matching was used to select subpopulations with comparable baseline characteristics. Disability outcomes were compared in paired, pairwise-censored analyses adjusted for treatment persistence, visit density, and relapse rates. Results: Of the 2,381 included patients, 1,378 patients were matchable (treated n=689, untreated n=689). Median pairwise-censored follow-up was 2.1 years (quartiles 1.2-3.8 years). No difference in the risk of 6-month sustained disability progression was observed between the groups (hazard ratio [HR] 0.9, 95% confidence interval [CI] 0.7-1.1, p=0.27). We also did not find differences in any of the secondary endpoints: risk of reaching Expanded Disability Status Scale (EDSS) score $ 7 (HR 0.6, 95% CI 0.4-1.1, p=0.10), sustained disability reduction (HR 1.0, 95% CI 0.8-1.3, p=0.79), or change in disability burden (area under the EDSS-time curve, beta=20.05, p=0.09). Secondary and sensitivity analyses confirmed the results. Conclusions: Our pooled analysis of the currently available disease-modifying agents used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years. Classification of evidence: This study provides Class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression. BiogenBiogen; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; University of MelbourneUniversity of Melbourne; MerckMerck & Company; NovartisNovartis; BayerBayer AG; GenzymeGenzyme Corporation; Teva; Sanofi-AventisSanofi-Aventis This study was financially supported by Biogen (Fellowship in MS Registries Research), the National Health and Medical Research Council (practitioner fellowship 1,080,518; project grants 1,083,539 and 1,129,189; and Centre for Research Excellence 1,001,216), and the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship). The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer, Genzyme, Teva, and Sanofi-Aventis. The study was conducted separately and apart from the guidance of the sponsors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|